ITALY - Finlombarda invests EUR 1m in biotech business

The business commercialises innovative transgenic products to facilitate and accelerate the development process of new drugs in the pharmaceutical industry and the detection of toxic compounds present in the environment or in the food chain. TOP srl was established at the end of 2006 by Professor Adriana Maggi and by Dr. Paolo Ciana of University of Milan, to operate in the field of transgenic research. Its approach is based on introducing a gene in the genome of animals (mice), which produces a protein that can be readily measured in the presence of the drug or toxic compound being studied. The effect of the drug or toxic compound can thus made readily visible inside the healthy, living animal using non-invasive imaging methods (the same methods used in human diagnostics, such as PET (Positron Emission Tomography), MRI (Magnetic Resonance Imaging and other methods).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe